Associated Papers
Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer.
Gust KM et al.
Molecular Cancer Therapeutics, 2013
No evidence of FGFR3 mutations in prostate cancer.
Zuiverloon TC et al.
The Prostate, 2011
Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping.
Miyake M et al.
Biochemical and Biophysical Research Communications, 2007
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.
Tomlinson DC et al.
The Journal of Pathology, 2007
A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine.
van Oers JM et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005
The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
Ouerhani S et al.
Cancer Biomarkers : Section a of Disease Markers, 0
Select a paper to view details